Nyxoah Announces Positive Trial Results and Plans Label Expansion for Sleep Therapy Device
On Thursday, Nyxoah's stock rose following positive results from a pivotal trial involving its Genio system sleep therapy device in patients with Complete Concentric Collapse (CCC) of the soft palate. The Belgian MedTech company announced plans to seek an expansion of the label for this product based on these findings. The Genio system is already approved as a treatment option, and the new data supports broader use among specific patient groups. This development has led to increased investor confidence in Nyxoah's potential market reach with its existing technology.
Tickers: $NYXH
Topics: Clinical Trials Medical Technology Sleep Therapy Device